Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Strategy in Emerging Markets: Scale, Diversification and Access

This article was originally published in PharmAsia News

Executive Summary

Branded products are key to emerging markets, where they tend to have long lifecycles that extend well beyond patent expiration, GlaxoSmithKline's president of emerging markets Abbas Hussain told investors at a Sanford F. Bernstein conference May 6

You may also be interested in...



Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?

The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics.

Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?

The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics.

Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?

Egypt, an emerging pharmaceutical market, is implementing a series of healthcare and drug pricing reforms. The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics in the country

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC071601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel